Navigation Links
Gilde Healthcare III Portfolio Company Definiens Establishes Advisory Board
Date:3/27/2013

NEW YORK, March 27, 2013 /PRNewswire/ -- Definiens, the global leader of image and data analysis solutions for quantitative digital pathology, today announced it has appointed an Advisory Board comprising renowned industry experts and visionaries in digital pathology. As part of its market expansion strategy, Definiens established the new Board to provide independent advice on trends and opportunities in tissue diagnostics and clinical digital pathology. Members of the Advisory Board include: - Ron A. Andrews , President, Medical Sciences, Life Technologies and former CEO of Clarient and CEO of GE Molecular Diagnostics - Prof. Uwe Bicker , Dean of the Medical Faculty Mannheim, University of Heidelberg and a member of the board of directors of Sanofi SA - Prof. Manfred Dietel , Director, Institute of Pathology, Charite Berlin and chairman of the German Society for Pathology - Eric F. Glassy, M.D., Medical Director, Pathology, Inc. and chairman of the Digital Pathology Working Group of the College of American Pathologists - Prof. Gerd Binnig , Founder and CTO, Definiens (Moderator). "Definiens is working to advance personalized medicine by contributing to the development of next generation diagnostics, and bringing those novel diagnostics into clinical practice. Our innovations have the potential to transform daily clinical practice for the benefit of both patients and pathologists, particularly in oncology," said Thomas Heydler , CEO of Definiens. "We will greatly benefit from the wealth of experience of the Advisory Board members while expanding our business into tissue diagnostics and clinical digital pathology." As part of its goal to guide Definiens during the company's expansion, the Advisory Board will discuss trends in digital pathology and highlight opportunities for image and data analysis to revolutionize clinical practice in pathology. Specific topics of discussion will include pathology workflow, tissue diagnostic test development, personalized medicine and next-generation cancer treatment, as well as future technology and market requirements. Definiens founder and Nobel laureate, Professor Gerd Binnig , will catalyze the discussions. "With the novel opportunities enabled by digital pathology, progress in diagnosing and treating cancer will be accelerated. The visionary power and expertise brought together in the Definiens Advisory Board will be invaluable on our path towards bringing advanced image analysis to clinical pathology," said Prof. Gerd Binnig , Founder and CTO of Definiens. About Definiens Definiens is the leading provider of image analysis and data mining solutions for life sciences, tissue diagnostics and clinical digital pathology. Definiens software provides detailed cell-by-cell readouts from target structures on whole tissue slides, and allows the correlation of this information with data derived from other sources. By automating analysis workflows, Definiens helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and support better decisions in research, diagnostics and therapy. Definiens' vision is to open new fields of research, to contribute to development of personalized medicine and to significantly improve the quality of patients' lives. Definiens is headquartered in Munich, Germany and has offices throughout the United States. Further information is available at www.definiens.com. Media Contact Definiens AG Dr Florian Leiss Manager Marketing Communications +49 (89) 2311-8024 fleiss@definiens.com About Gilde Healthcare Partners Gilde Healthcare Partners (Utrecht, The Netherlands and Cambridge, USA) is a transatlantic venture and growth capital firm focused on private healthcare technology and service companies. It has over €450 million ($600 million) under management and is actively looking to lead new investments in therapeutics, diagnostics, medical devices and healthcare services. Gilde successfully builds healthcare businesses across Europe and US, investing up to €15 million ($20 million) in a single portfolio company. For a list of Gilde's portfolio companies please visit the website at www.gildehealthcare.com.

Media Contact: Dr Florian  Leiss , +49 (89) 2311-8024, fleiss@definiens.com


'/>"/>
SOURCE Gilde Healthcare Partners
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Attendees Save Up To $800 on Boston-area Pharmaceutical and Healthcare Conferences, Early Bird Discounts Expiring April 27
2. Early Bird Discounts Available on International Healthcare and Biotechnology Conferences, Save Up To $600 with Global Information
3. Boston Healthcare Associates Roundtable Explores Challenges and Opportunities Surrounding the Value of Big Data within the Life Sciences
4. Bioethics for Beginners: 60 Cases and Cautions from the Moral Frontier of Healthcare
5. Early Bird Offers on Healthcare and Biotechnology Conferences, Save Up To 20% by Registering with Global Information
6. Premier Healthcare Renews Supplier Agreement with Masimo
7. BGI, GE Healthcare team up on pioneering stem cell science projects
8. VTT and GE Healthcare developing novel biomarkers to predict Alzheimers disease
9. Pilot Results Move GHX Closer to Delivery of Healthcare Industrys First Implantable Device Supply Chain Solution
10. BUSM/VA Boston Healthcare System investigators identify new gene linked to PTSD
11. Mount Sinai grad student, 25, named to Forbes 30 Under 30 in Science and Healthcare
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... and PORTLAND, Ore. , ... and the Avamere Family of Companies (Avamere Health Services, ... announced a six-month research study that will apply the ... eldercare at senior living and health centers. By analyzing ... hopes to gain insights into physical and environmental conditions, ...
(Date:2/13/2017)...  RSA Conference -- RSA, a Dell Technologies business, ... enhance fraud detection and investigation across digital environments ... & Risk Intelligence Suite. The new platform is ... from internal and external sources as well as ... from targeted cybercrime attacks. "Fraudsters are ...
(Date:2/8/2017)... Feb. 8, 2017 About Voice Recognition Biometrics ... match it against a stored voiceprint template. Acoustic ... cadence, and tone are compared to distinguish between ... installation, as most PCs already have a microphone ... Voice recognition biometrics are most likely to be ...
Breaking Biology News(10 mins):
(Date:3/22/2017)... 2017 MarketNewsUpdates.com News Commentary  ... The traditional ways ... pressured as of late due to the rise of the ... a dramatic impact on patient,s quality of life as Biotech ... identifying new forms of opioid formulations that prevent abuse. Biotech ...
(Date:3/22/2017)... March 22, 2017   VWR ... of product and service solutions to laboratory ... has acquired EPL Archives, Inc., an international ... the entire regulated product research, development and ... storage and ancillary services. EPL Archives is ...
(Date:3/22/2017)... ... March 21, 2017 , ... Proper glycosylation is ... the desired increase and/or decrease in antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity, there ... therapeutic antibodies. , To meet this demand, the team at SCIEX has ...
(Date:3/22/2017)... ... March 21, 2017 , ... The Conference Forum has announced the ... be held on May 10-11, 2017, at the Colonnade Hotel in Boston, MA. The ... Medical Officer peer-to-peer learning, benchmarking and support. , “The Chief Medical Officer faces a ...
Breaking Biology Technology: